1859949-36-2

Usage

Uses

Used in Pharmaceutical Industry:
(2-o-tolyl-cyclopropyl)-carbamic acid tert-butyl ester is used as an intermediate in the synthesis of pharmaceuticals for its ability to selectively bind to and modulate the activity of certain enzymes or receptors in the body.
Used in Development of New Therapeutic Agents:
(2-o-tolyl-cyclopropyl)-carbamic acid tert-butyl ester is used as a potential candidate in the development of new therapeutic agents due to its demonstrated biological activity, which could be harnessed for various medical applications.

Upstream product

• 24393-48-4 ethyl trans-2-methylcinnamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 70625-62-6 methyl (E)-3-(2-methylphenyl)-2-propenoate 
• 939-57-1 (E)-3-(2-methylphenyl)acrylic acid 
• 75-65-0 tert-butyl alcohol 
• 1821802-95-2 2-(o-tolyl)cyclopropane-1-carboxylic acid 

Relevant academic research and scientific papers

Oxidative ring-opening of ferrocenylcyclopropylamines to N-ferrocenylmethyl β-hydroxyamides

The in situ reduction of ferrocenyl cyclopropylimines to the corresponding amines triggers a facile oxidative ring-opening to yield the formal four-electron oxidation products: N-ferrocenylmethyl β-hydroxyamides. This process is believed to proceed via generation of a ferrocinium ion in the presence of air, leading to facile formation of a distonic radical cation that is ultimately trapped by oxygen.

Exploring distal regions of the A3 adenosine receptor binding site: Sterically constrained N6-(2-phenylethyl)adenosine derivatives as potent ligands

We synthesized phenyl ring-substituted analogues of N6-(1S,2R)- (2-phenyl-1-cyclopropyl)adenosine, which is highly potent in binding to the human A3AR with a Ki value of 0.63nM. The effects of these structural changes on affinity at human and rat adenosine receptors and on intrinsic efficacy at the hA3AR were measured. A 3-nitrophenyl analogue was resolved chromatographically into pure diastereomers, which displayed 10-fold stereoselectivity in A3AR binding in favor of the 1S,2R isomer. A molecular model defined a hydrophobic region (Phe168) in the putative A3AR binding site around the phenyl moiety. A heteroaromatic group (3-thienyl) could substitute for the phenyl moiety with retention of high affinity of A3AR binding. Other related N6-substituted adenosine derivatives were included for comparison. Although the N 6-(2-phenyl-1-cyclopropyl) derivatives were full A3AR agonists, several other derivatives had greatly reduced efficacy. N 6-Cyclopropyladenosine was an A3AR antagonist, and adding either one or two phenyl rings at the 2-position of the cyclopropyl moiety restored efficacy. N6-(2,2-Diphenylethyl)adenosine was an A 3AR antagonist, and either adding a bond between the two phenyl rings (N6-9-fluorenylmethyl) or shortening the ethyl moiety (N 6-diphenylmethyl) restored efficacy. A QSAR study of the N 6 region provided a model that was complementary to the putative A3AR binding site in a rhodopsin-based homology model. Thus, a new series of high-affinity A3AR agonists and related nucleoside antagonists was explored through both empirical and theoretical approaches.